Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021

SELL
$6.5 - $10.53 $1,241 - $2,011
-191 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$3.32 - $5.34 $1,809 - $2,910
-545 Reduced 74.05%
191 $1,000
Q1 2020

Jun 11, 2020

BUY
$2.12 - $6.8 $1,155 - $3,706
545 Added 285.34%
736 $3,000
Q1 2020

May 07, 2020

BUY
$2.12 - $6.8 $404 - $1,298
191 New
191 $651,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.